Theravance Biopharma Azioni (NASDAQ: TBPH)

Ultime notizie per Theravance Biopharma (NASDAQ:TBPH) Azioni

Theravance Biopharma

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Theravance Biopharma, Inc. - Ordinary Shares

Theravance Biopharma Inc

Across the recent three months, 4 analysts have shared their insights on Theravance Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $12.25, with a high estimate of $15.00 and a low estimate of $9.00. A 18.33% drop is evident in the current average compared to the previous average price target of $15.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1726488035_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of Theravance Biopharma's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$15.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Marc Frahm</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$9.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>David Risinger</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$10.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Theravance Biopharma. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Theravance Biopharma compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Theravance Biopharma's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Theravance Biopharma's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/TBPH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Theravance Biopharma analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Theravance Biopharma</h2>
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
<h3>Theravance Biopharma: Financial Performance Dissected</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Theravance Biopharma displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 3.69%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Theravance Biopharma's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -115.94% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Theravance Biopharma's ROE excels beyond industry benchmarks, reaching -8.29%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -4.51%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.24.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

TBPH

Unveiling 4 Analyst Insights On Theravance Biopharma

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Theravance Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) with a Buy and maintains $15 price target.

News

Price Target

Reiteration

HC Wainwright & Co. Reiterates Buy on Theravance Biopharma, Maintains $15 Price Target

Theravance Biopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tbph#NASDAQ">TBPH</a>) reported a second-quarter 2024 adjusted net loss of 13 cents per share, which was wider than the Zacks Consensus Estimate of a loss of 9 cents per share. In the year-ago quarter, the company had reported a loss of 13 cents per share.
The reported loss excludes share-based compensation expense, non-cash impairment of long-lived assets, income tax expense and non-cash interest expense. Including these items, the company reported a loss of 34 cents per share in the second quarter.
Total revenues came in at $14.3 million, missing the Zacks Consensus Estimate of $16 million. Revenues, however, rose 4.4% year over year owing to increased collaboration revenues from partner Viatris (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtrs#NASDAQ">VTRS</a>).
<h3>Quarter in Detail</h3>
The top line fully comprised Viatris&#39; collaboration revenues in relation to Yupelri (revefenacin) sales.
Theravance and Viatris have collaborated for the development and commercialization of Yupelri.
Viatris and Theravance share U.S. profits and losses received in connection with the commercialization of Yupelri. While Viatris gets 65% of the profits, Theravance receives 35%. Viatris collaboration revenues include Theravance&#39;s 35% share of net sales of Yupelri, as well as its proportionate amount of the total shared costs incurred by the two companies.
VTRS recognizes product sales from Yupelri and also owns a stake in Theravance.
Shares of Theravance have declined 14.7% year to date compared with the industry&#39;s decline of 3.3%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/41/73498.jpg?v=151316647" />
Image Source: Zacks Investment Research
Research and development expenses (excluding share-based compensation) totaled $8.8 million, up almost 17.3% from the year-ago quarter&#39;s level. Selling, general and administrative expenses (excluding share-based compensation) declined around 13.4% year over year to $12.9 million.
As of Jun 30, 2024, Theravance had cash, cash equivalents and marketable securities worth $96.1 million compared with $100 million as of Mar 31, 2024.
<h3>2024 Guidance</h3>
Theravance continues to expect adjusted R&amp;D expenses (excluding share-based compensation) in the $30-$36 million range. Adjusted SG&amp;A expenses (excluding share-based compensation) are projected between $45 million and $55 million.
TBPH continues to expect share-based compensation expenses of&nbsp;$18-$22 million in 2024.
For the remainder of 2024, TBPH now expects levels of both adjusted losses and cash burn to be the same as the first half of 2024. Earlier, the company expected to achieve breakeven in the second half of 2024 while expecting limited cash burn for the year.
<h3>Pipeline Updates</h3>
Theravance is developing an investigational candidate, ampreloxetine (TD-9855), a norepinephrine reuptake inhibitor for the treatment of neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy. The FDA has granted Orphan Drug designation to ampreloxetine for the given indication.
The company initiated the phase III CYPRESS study evaluating ampreloxetine for nOH MSA in the first quarter of 2024. The CYPRESS study is expected to complete patient enrollment by mid-2025, which was earlier expected to be completed by the second half of 2024. Top-line data from the same is expected almost six months after enrollment is completed. TBPH plans to submit regulatory filings for ampreloxetine if the study data is found to be positive.
<div class="chart_embed">
<h3>Theravance Biopharma, Inc. Price, Consensus and EPS Surprise</h3>
<img alt="Theravance Biopharma, Inc. Price, Consensus and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/95/1722950875.png" style="height:265px; width:574px" title="" />
Theravance Biopharma, Inc. price-consensus-eps-surprise-chart | Theravance Biopharma, Inc. Quote
</div>
<h3>Zacks Rank &amp; Stocks to Consider</h3>
Theravance currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the healthcare sector are Halozyme Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/halo#NASDAQ">HALO</a>) and Repare Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rptx#NASDAQ">RPTX</a>), each sporting a Zacks Rank #1 (Strong Buy) at present.
In the past 60 days, estimates for Halozyme&#39;s 2024 earnings per share have improved from $3.69 to $3.90. Earnings per share estimates for 2025 have improved from $4.50 to $4.81. Year to date, shares of HALO have soared 40.9%.
HALO&#39;s earnings beat estimates in three of the trailing four quarters and met the same on the remaining occasion, the average surprise being 9.40%.
In the past 60 days, estimates for Repare Therapeutics&#39; 2024 loss per share have narrowed from $2.42 to $2.35. Loss per share estimates for 2025 have narrowed from $3.29 to $3.21. Year to date, shares of RPTX have plunged 57.2%.
RPTX&#39;s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 123.58%.
<a href="https://www.zacks.com/stock/news/2317149/theravance-tbph-q2-loss-wider-than-expected-revenues-rise-y-y?cid=CS-BENZ-FT-analyst_blog|earnings_article-2317149">To read this article on Zacks.com click here.</a>

Biotech

Earnings

Earnings Beats

Penny Stocks

Guidance

Small Cap

Markets

Trading Ideas

General

HALO

RPTX

VTRS

Theravance Q2 Loss Wider Than Expected, Revenues Rise Y/Y

HC Wainwright &amp; Co. analyst Douglas Tsao maintains Theravance Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) with a Buy and lowers the price target from $20 to $15.

HC Wainwright & Co. Maintains Buy on Theravance Biopharma, Lowers Price Target to $15

WIIM

Theravance Biopharma shares are trading lower after the company reported mixed Q2 financial results. Also, Leerink Partners downgraded the stock from Outperform to Market Perform and lowered its price target from $15 to $10.

4 analysts have expressed a variety of opinions on Theravance Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $14.75, with a high estimate of $20.00 and a low estimate of $9.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.67%. 
<img src="https://www.benzinga.com/files/images/story/2024/1722963640_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Theravance Biopharma by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marc Frahm</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$9.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>David Risinger</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$10.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>-</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Theravance Biopharma. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Theravance Biopharma compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Theravance Biopharma's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Theravance Biopharma's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/TBPH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Theravance Biopharma analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Theravance Biopharma</h2>
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
<h3>Financial Milestones: Theravance Biopharma's Journey</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Theravance Biopharma's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 39.22%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Theravance Biopharma's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -80.42%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Theravance Biopharma's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -5.58%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Theravance Biopharma's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -3.1%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Theravance Biopharma's debt-to-equity ratio is below the industry average at 0.23, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cracking The Code: Understanding Analyst Reviews For Theravance Biopharma

TD Cowen analyst Marc Frahm maintains Theravance Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) with a Hold and lowers the price target from $10 to $9.

TD Cowen Maintains Hold on Theravance Biopharma, Lowers Price Target to $9

Leerink Partners analyst David Risinger downgrades Theravance Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) from Outperform to Market Perform and lowers the price target from $15 to $10.

Downgrades

Leerink Partners Downgrades Theravance Biopharma to Market Perform, Lowers Price Target to $10

The Company continues to expect full year 2024 R&amp;D expenses of&nbsp;$30 million&nbsp;to&nbsp;$36 million&nbsp;and SG&amp;A expenses of&nbsp;$45 million&nbsp;to&nbsp;$55 million, in each case excluding share-based compensation.
The Company continues to expect full year share-based compensation expenses of&nbsp;$18 million&nbsp;to&nbsp;$22 million.

Theravance Biopharma Now Expects FY24 Levels Of Both Non-GAAP Losses And Cash Burn To Be Similar To First Half Actuals 2024

Theravance Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.21) by 38.1 percent. The company reported quarterly sales of $14.256 million which missed the analyst consensus estimate of $15.453 million by 7.75 percent. This is a 3.69 percent increase over sales of $13.749 million the same period last year.

Earnings Misses

Theravance Biopharma Q2 2024 Adj. EPS $(0.13) Beats $(0.21) Estimate, Sales $14.256M Miss $15.453M Estimate

U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Wednesday.
Shares of Mama&#8217;s Creations Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAMA#NASDAQ">MAMA</a>) fell in today's pre-market trading following <a href="https://www.benzinga.com/quote/MAMA/earnings">first-quarter results</a>.
Mama's Creations posted downbeat earnings for its first quarter, while sales topped estimates.
Mama&#8217;s Creations shares declined 3% to $6.97 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>U-BX Technology Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBXG#NASDAQ">UBXG</a>) shares dipped 15.4% to $9.83 in pre-market trading after jumping 21% on Tuesday.</li>
<li>Ferrovial SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FER#NASDAQ">FER</a>) shares declined 5.8% to $38.99 in pre-market trading after gaining 5% on Tuesday.</li>
<li>Theravance Biopharma Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) shares fell 5.8% to $8.31 in pre-market trading.</li>
<li>Sage Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) shares declined 5.5% to $10.02 in pre-market trading. The company recently announced results from its Phase 2 Huntington's Disease clinical study.</li>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) shares fell 5.4% to $28.83 in pre-market trading after surging around 23% on Tuesday. GameStop announced completion of previously disclosed &#8220;at-the-market&#8221; equity offering program.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) shares fell 3.7% to $9.51 in pre-market trading after gaining 16% on Tuesday.</li>
<li>NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) shares fell 3.4% to $4.31 in pre-market trading after declining over 5% on Tuesday.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/06/39285495/oracle-broadcom-and-other-3-key-stocks-to-watch-on-wednesday">Oracle, Broadcom And Other 3 Key Stocks To Watch On Wednesday</a>
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>

Pre-Market Outlook

Movers

ASTS

MAMA

SAGE

UBXG

Mama's Creations, GameStop And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Theravance Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) with a Buy and maintains $20 price target.

HC Wainwright & Co. Reiterates Buy on Theravance Biopharma, Maintains $20 Price Target

Theravance Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.25) by 4 percent. The company reported quarterly sales of $14.503 million which beat the analyst consensus estimate of $13.963 million by 3.87 percent. This is a 39.22 percent increase over sales of $10.417 million the same period last year.

Theravance Biopharma Q1 2024 GAAP EPS $(0.24) Beats $(0.25) Estimate, Sales $14.503M Beat $13.963M Estimate

Theravance Biopharma shares are trading higher after BTIG initiated coverage on the stock with a Buy rating and a $21 price target.

BTIG analyst Julian Harrison initiates coverage on Theravance Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) with a Buy rating and announces Price Target of $21.

Initiation

BTIG Initiates Coverage On Theravance Biopharma with Buy Rating, Announces Price Target of $21

Theravance Biopharma Expects Non-GAAP Loss In H1 Of 2024 And Approach Non-GAAP Breakeven In H2 Of 2024; Limited Cash Burn Expected In 2024

Theravance Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) reported its Q4 earnings results on Monday, February 26, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Theravance Biopharma missed estimated earnings by -13.0%, reporting an EPS of $-0.17 versus an estimate of $-0.15.
Revenue was up $2.92 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.04 which was followed by a 5.0% increase in the share price the next day.
Here's a look at Theravance Biopharma's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.21</td>
<td>-0.16</td>
<td>-0.26</td>
<td>-0.17</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.17</td>
<td>-0.13</td>
<td>-0.24</td>
<td>-0.21</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>15.00M</td>
<td>15.24M</td>
<td>13.84M</td>
<td>15.73M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>15.69M</td>
<td>13.75M</td>
<td>10.42M</td>
<td>14.65M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Theravance Biopharma <a href="https://www.benzinga.com/quote/TBPH/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Theravance Biopharma Q4 Earnings

Theravance Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.15) by 13.33 percent. The company reported quarterly sales of $17.57 million which missed the analyst consensus estimate of $17.68 million by 0.67 percent. This is a 19.91 percent increase over sales of $14.65 million the same period last year.

Theravance Biopharma Q4 2023 GAAP EPS $(0.17) Misses $(0.15) Estimate, Sales $17.57M Miss $17.68M Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; Kosmos Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOS#NYSE">KOS</a>) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million.
&bull; Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) is estimated to report quarterly loss at $0.37 per share on revenue of $28.61 million.
&bull; Li Auto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) is estimated to report quarterly earnings at $0.29 per share on revenue of $5.48 billion.
&bull; Clear Channel Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCO#NYSE">CCO</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $610.14 million.
&bull; Lincoln Educational Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINC#NASDAQ">LINC</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $96.20 million.
&bull; BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) is projected to report quarterly loss at $0.24 per share on revenue of $90.01 million.
&bull; Fresh Del Monte Produce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDP#NYSE">FDP</a>) is estimated to report quarterly earnings at $0.30 per share on revenue of $1.03 billion.
&bull; Gilat Satellite Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILT#NASDAQ">GILT</a>) is estimated to report quarterly earnings at $0.07 per share on revenue of $75.98 million.
&bull; Itron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRI#NASDAQ">ITRI</a>) is likely to report quarterly earnings at $0.75 per share on revenue of $570.23 million.
&bull; Playtika Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTK#NASDAQ">PLTK</a>) is estimated to report quarterly earnings at $0.17 per share on revenue of $629.98 million.
&bull; Enlight Renewable Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENLT#NASDAQ">ENLT</a>) is projected to report earnings for its Fiscal Year 2023.
&bull; Surgery Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGRY#NASDAQ">SGRY</a>) is likely to report quarterly earnings at $0.38 per share on revenue of $741.40 million.
&bull; Alpha Metallurgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMR#NYSE">AMR</a>) is projected to report quarterly earnings at $9.07 per share on revenue of $796.65 million.
&bull; Elanco Animal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) is projected to report quarterly earnings at $0.11 per share on revenue of $1.00 billion.
&bull; Freshpet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPT#NASDAQ">FRPT</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $204.36 million.
&bull; Kaspi.kz (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSPI#NASDAQ">KSPI</a>) is likely to report earnings for its fourth quarter.
&bull; Public Service Enterprise (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEG#NYSE">PEG</a>) is projected to report quarterly earnings at $0.52 per share on revenue of $2.40 billion.
&bull; Domino&#39;s Pizza (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) is likely to report quarterly earnings at $4.37 per share on revenue of $1.42 billion.
&bull; Fidelity National Info (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) is expected to report quarterly earnings at $0.94 per share on revenue of $2.53 billion.
&bull; Pilgrims Pride (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPC#NASDAQ">PPC</a>) is estimated to report quarterly earnings at $0.40 per share on revenue of $4.47 billion.
&bull; Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) is expected to report quarterly loss at $0.12 per share on revenue of $5.21 million.
<h3>Companies Reporting After The Bell</h3>
&bull; Innovative Ind Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>) is likely to report earnings for its fourth quarter.
&bull; Diversified Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHC#NASDAQ">DHC</a>) is likely to report earnings for its fourth quarter.
&bull; Franklin Street Props (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FSP#AMEX">FSP</a>) is likely to report earnings for its fourth quarter.
&bull; Dril-Quip (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRQ#NYSE">DRQ</a>) is estimated to report quarterly earnings at $0.18 per share on revenue of $118.50 million.
&bull; Revolution Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVMD#NASDAQ">RVMD</a>) is likely to report quarterly loss at $0.90 per share on revenue of $1.09 million.
&bull; FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) is expected to report quarterly loss at $0.42 per share on revenue of $38.90 million.
&bull; Quanterix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTRX#NASDAQ">QTRX</a>) is likely to report quarterly loss at $0.32 per share on revenue of $29.84 million.
&bull; Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) is expected to report quarterly earnings at $0.17 per share on revenue of $75.89 million.
&bull; Sezzle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEZL#NASDAQ">SEZL</a>) is projected to report earnings for its fourth quarter.
&bull; Aarons (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAN#NYSE">AAN</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $542.07 million.
&bull; Archer Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) is likely to report quarterly loss at $0.28 per share on revenue of $320 thousand.
&bull; ATI Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATIP#NYSE">ATIP</a>) is projected to report quarterly loss at $3.74 per share on revenue of $177.39 million.
&bull; Air Transport Services Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATSG#NASDAQ">ATSG</a>) is expected to report quarterly earnings at $0.28 per share on revenue of $523.06 million.
&bull; CarGurus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) is likely to report quarterly earnings at $0.34 per share on revenue of $220.05 million.
&bull; Dorman Prods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DORM#NASDAQ">DORM</a>) is likely to report quarterly earnings at $1.41 per share on revenue of $496.72 million.
&bull; Ellington Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFC#NYSE">EFC</a>) is likely to report quarterly earnings at $0.40 per share on revenue of $42.67 million.
&bull; Erie Indemnity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIE#NASDAQ">ERIE</a>) is likely to report quarterly earnings at $2.02 per share on revenue of $772.57 million.
&bull; Fate Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATE#NASDAQ">FATE</a>) is estimated to report quarterly loss at $0.52 per share on revenue of $1.59 million.
&bull; Helix Energy Solns Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLX#NYSE">HLX</a>) is estimated to report quarterly earnings at $0.10 per share on revenue of $315.60 million.
&bull; AES (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>) is estimated to report quarterly earnings at $0.67 per share on revenue of $3.36 billion.
&bull; Carlyle Secured Lending (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGBD#NASDAQ">CGBD</a>) is projected to report quarterly earnings at $0.52 per share on revenue of $56.74 million.
&bull; iRobot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRBT#NASDAQ">IRBT</a>) is projected to report quarterly loss at $2.11 per share on revenue of $307.99 million.
&bull; Douglas Dynamics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLOW#NYSE">PLOW</a>) is estimated to report quarterly loss at $0.16 per share on revenue of $98.97 million.
&bull; Offerpad Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPAD#NYSE">OPAD</a>) is projected to report quarterly loss at $0.47 per share on revenue of $249.64 million.
&bull; Postal Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTL#NYSE">PSTL</a>) is projected to report earnings for its fourth quarter.
&bull; PowerSchool Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWSC#NYSE">PWSC</a>) is likely to report quarterly earnings at $0.21 per share on revenue of $183.44 million.
&bull; SBA Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBAC#NASDAQ">SBAC</a>) is likely to report quarterly earnings at $1.37 per share on revenue of $682.17 million.
&bull; SES AI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) is projected to report earnings for its fourth quarter.
&bull; Solaris Oilfield Infra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOI#NYSE">SOI</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $65.55 million.
&bull; TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) is projected to report quarterly loss at $0.03 per share on revenue of $68.51 million.
&bull; Vitesse Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTS#NYSE">VTS</a>) is likely to report quarterly earnings at $0.43 per share on revenue of $61.81 million.
&bull; Sterling Infrastructure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRL#NASDAQ">STRL</a>) is estimated to report quarterly earnings at $1.00 per share on revenue of $522.45 million.
&bull; Theravance Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) is projected to report quarterly loss at $0.15 per share on revenue of $17.68 million.
&bull; Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) is expected to report quarterly earnings at $1.17 per share on revenue of $274.44 million.
&bull; Helios Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLIO#NYSE">HLIO</a>) is projected to report quarterly earnings at $0.27 per share on revenue of $183.35 million.
&bull; Asure Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASUR#NASDAQ">ASUR</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $26.39 million.
&bull; Heico (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HEI#NYSE">HEI</a>) is estimated to report quarterly earnings at $0.74 per share on revenue of $894.28 million.
&bull; Primoris Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRIM#NYSE">PRIM</a>) is likely to report quarterly earnings at $0.67 per share on revenue of $1.55 billion.
&bull; Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) is likely to report quarterly earnings at $1.47 per share on revenue of $1.92 billion.
&bull; Agora (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/API#NASDAQ">API</a>) is likely to report quarterly loss at $0.09 per share on revenue of $41.74 million.
&bull; EverQuote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVER#NASDAQ">EVER</a>) is projected to report quarterly loss at $0.32 per share on revenue of $49.81 million.
&bull; SI-BONE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIBN#NASDAQ">SIBN</a>) is expected to report quarterly loss at $0.28 per share on revenue of $37.61 million.
&bull; Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) is projected to report quarterly loss at $0.02 per share on revenue of $245.82 million.
&bull; Trex Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TREX#NYSE">TREX</a>) is likely to report quarterly earnings at $0.19 per share on revenue of $193.29 million.
&bull; Adtran Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTN#NASDAQ">ADTN</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $228.30 million.
&bull; RLJ Lodging (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLJ#NYSE">RLJ</a>) is projected to report quarterly earnings at $0.00 per share on revenue of $314.28 million.
&bull; KNOT Offshore Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNOP#NYSE">KNOP</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $71.33 million.
&bull; ONEOK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>) is expected to report quarterly earnings at $1.21 per share on revenue of $5.89 billion.
&bull; Unity Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) is likely to report quarterly loss at $0.42 per share on revenue of $564.02 million.
&bull; Everbridge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVBG#NASDAQ">EVBG</a>) is projected to report quarterly earnings at $0.49 per share on revenue of $114.66 million.
&bull; MidCap Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFIC#NASDAQ">MFIC</a>) is expected to report quarterly earnings at $0.43 per share on revenue of $67.63 million.
&bull; Zoom Video Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) is projected to report quarterly earnings at $1.15 per share on revenue of $1.13 billion.
&bull; Heidrick &amp; Struggles Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSII#NASDAQ">HSII</a>) is estimated to report quarterly earnings at $0.68 per share on revenue of $248.12 million.
&bull; SkyWater Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYT#NASDAQ">SKYT</a>) is projected to report quarterly loss at $0.12 per share on revenue of $74.84 million.
&bull; FS KKR Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSK#NYSE">FSK</a>) is estimated to report quarterly earnings at $0.75 per share on revenue of $453.28 million.
&bull; CrossAmerica Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAPL#NYSE">CAPL</a>) is expected to report quarterly earnings at $0.22 per share on revenue of $1.11 billion.
&bull; PubMatic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PUBM#NASDAQ">PUBM</a>) is projected to report quarterly earnings at $0.20 per share on revenue of $78.20 million.
&bull; MasterBrand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBC#NYSE">MBC</a>) is projected to report quarterly earnings at $0.27 per share on revenue of $666.70 million.
&bull; Albany Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIN#NYSE">AIN</a>) is expected to report quarterly earnings at $0.82 per share on revenue of $298.26 million.
&bull; New Mountain Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMFC#NASDAQ">NMFC</a>) is likely to report quarterly earnings at $0.40 per share on revenue of $93.28 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

ACHR

ADTN

ADUS

ASUR

ATIP

ATSG

BCRX

CAPL

CARG

CGBD

CRGO

DORM

ELAN

ENLT

ERIE

EVBG

EVER

FATE

FGEN

FRPT

GILT

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HLIO

HSII

IIPR

IRBT

ITRI

KNOP

KRYS

KSPI

LINC

Citigroup Financial 300% Minupon Princ Protected Nts for Russell 2000 Index

MFIC

NMFC

OPAD

PLOW

PLTK

PRIM

PSTL

PUBM

PWSC

QTRX

RVMD

SBAC

SEZL

SGRY

SIBN

SKYT

STAA

STRL

TMDX

TREX

WDAY

Earnings Scheduled For February 26, 2024

Theravance Biopharma, Inc. (TBPH) Q2 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Theravance Biopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/tbph-stock-quote/">TBPH</a>) just reported results for the second quarter of 2024.<ul><li>Theravance Biopharma reported earnings per share of -13 cents. This was above the analyst estimate for EPS of -21 cents.</li><li>The company reported revenue of $14.26 million.</li><li>This was 7.73% worse than the analyst estimate for revenue of $15.45 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/tbph-stock-earnings-theravance-biopharma-for-q2-of-2024/">TBPH Stock Earnings: Theravance Biopharma Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

TBPH Stock Earnings: Theravance Biopharma Beats EPS, Misses Revenue for Q2 2024

TD Cowen analyst Marc Frahm maintained a Hold rating on Theravance Biopharma (TBPH – Research Report) yesterday and set a price target of $9.00. Ma...

Theravance Biopharma: Hold Rating Maintained Amid Adjusted Sales Expectations and Development Delays

Douglas Tsao, an analyst from H.C. Wainwright, maintained the Buy rating on Theravance Biopharma (TBPH – Research Report). The associated price tar...

Maintaining Buy Rating on Theravance Biopharma: Long-term Value Amidst Short-term Challenges

Theravance Biopharma (TBPH – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Risinger ...

Hold Rating on Theravance Biopharma Amidst Revised Revenue Projections and Pipeline Delays

Theravance Biopharma ($TBPH) has seen its share price drop almost 20% in the past week after announcing mixed Q2 financial results. Expectations fo...

Small Cap Stocks: TBPH Stock Isn't Ideal for Short Term Investors

Klarman's Baupost adds WilScot, Capri, exits Altice USA, among others

Tracking Seth Klarman's Baupost Group Holdings - Q2 2024 Update

Theravance Biopharma ( ($TBPH) ) has issued an announcement. Theravance Biopharma, Inc. is set to engage in a Fireside Chat at the H.C. Wainwright ...

Theravance Biopharma Outlines Growth Strategy at Investment Conference

Theravance Biopharma (TBPH – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas Tsao fr...

Buy Rating Affirmed for Theravance Biopharma on Yupelri Growth and Ampreloxetine Pipeline Progress

ATUS

CLVT

CPRI

FTRE

GDHLF

GOOG

GOOGL

JAZZ

LBTYA

LBTYB

LBTYK

LSXMA

LSXMB

LSXMK

SOLV

VRSN

VSAT

Press Releases

Theravance Biopharma to Participate in an Upcoming Investor Conference

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024

Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024

Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024

Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Comments

Theravance Biopharma

Notizie

Ultime notizie per Theravance Biopharma (NASDAQ:TBPH) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO